Antigen-Specific Signaling by a Soluble, Dimeric Peptide/Major Histocompatibility Complex Class II/Fc Chimera Leading to T Helper Cell Type 2 Differentiation by Casares, Sofia et al.
 
543
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/99/08/543/11 $5.00
Volume 190, Number 4, August 16, 1999 543–553
http://www.jem.org
 
Antigen-speciﬁc Signaling by a Soluble, Dimeric
Peptide/Major Histocompatibility Complex Class II/Fc 
Chimera Leading to T Helper Cell Type 2 Differentiation
 
By Soﬁa Casares, Cong S. Zong, Dorel L. Radu, Alexander Miller, 
Constantin A. Bona, and Teodor-Doru Brumeanu
 
From the Department of Microbiology, Mount Sinai School of Medicine, New York, New York 10029
 
Summary
 
Interaction between a T cell receptor (TCR) and various ligands, i.e., anti-TCR antibodies,
superantigens, peptides, or altered peptide ligands in the context of major histocompatibility
complex (MHC) molecules can trigger different T helper cell (Th) effector functions. Herein,
we studied the T cell response induced by a soluble, dimeric peptide/MHC class II chimera,
namely hemagglutinin (HA)110-120/I-E
 
d
 
ab
 
/Fc
 
g
 
2a (DEF). We have previously demonstrated
that the soluble DEF molecule binds stably and specifically to HA110-120–specific TCRs ex-
pressed by a T cell hybridoma. Administration of DEF in vivo induced differentiation of rest-
ing and activated peptide-specific T cells toward a Th2 response,
 
 
 
as indicated by the increase of
interleukin (IL)-4, IL-10, and specific immunoglobulin (Ig)G1 antibodies and decrease of IL-2,
specific IgG2a antibodies, and cytotoxic T lymphocyte activity. In contrast to HA110-120
peptide presented by the DEF molecule to T cells, the nominal synthetic peptide induced a
predominant Th1 response, and the PR8 virus–derived HA110-120 peptides induced a mixed
Th1/Th2 response. Independent of antigen processing, soluble DEF was almost 2 logs more
potent in stimulating cognate T cells than the nominal peptide. Polarization of cognate T cells
toward the Th2 response occurred upon interaction of soluble DEF with TCR and CD4 mol-
ecules followed by early activation of p56
 
lck
 
 and ZAP-70 tyrosine kinases, and negative signal-
ing of the signal transducer and activator of transcription (STAT)4 pathway of Th1 differenti-
ation. DEF-like molecules may provide a new tool to study the mechanisms of signaling
toward Th2 differentiation and may also provide a potential immunotherapeutic approach to
modulate autoreactive T cells toward protective Th2 immune responses.
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R
 
ecent investigations on the functionality of CD4 T
cell–derived Th1 and Th2 responses have disclosed
new information on the pathogenesis of several infectious
and autoimmune diseases. The Th1 response is highly pro-
tective against intracellular parasites (1, 2) and acute al-
lograft rejection (3, 4), whereas the Th2 response protects
against organ-specific autoimmune diseases such as thy-
roiditis, insulin-dependent diabetes mellitus, multiple scle-
rosis, and Crohn’s disease (5). Although the genetic mecha-
nisms responsible for Th1 or Th2 development remain
elusive, the environmental factors, i.e., route of antigen ad-
ministration, dose of antigen, type of APCs, and the type of
adjuvants have been shown to play a critical role (6).
The primum movens toward Th differentiation depends
on the type of cytokines present in the microenvironment
(7). The IL-4 required for Th2 differentiation can be pro-
 
vided by a subset of CD4 NK1.1
 
1
 
 cells (8), naive CD4 T
cells after stimulation with IL-6 produced by APCs (9), or
progesterone (4). In a like manner, the IFN-
 
g
 
 required for
Th1 development can be provided by a subset of NK cells,
CD8 T cells, or naive CD4 T cells upon stimulation with
IL-12 secreted by dendritic cells, macrophages, and neutro-
phils (10). Binding of cytokines to their cognate receptors
induces phosphorylation-mediated activation of multiple
signaling molecules, including the signal transducers and
activators of transcription (STATs)
 
1
 
 (11). Activated STATs
rapidly translocate to the nucleus as homodimers or het-
erodimers and bind to cis-acting elements of the cytokine
promoter genes with concurrent gene activation and aug-
mentation of cytokine production. Whereas signaling of
IL-12R
 
b
 
1
 
b
 
2
 
 complex by IL-12 induces STAT4-dependent
IFN-
 
g
 
 secretion with consequent Th1 differentiation (12),
signaling of IL-4R
 
a
 
 by IL-4 induces STAT6-dependent
IL-4 secretion with consequent Th2 differentiation (13).
 
1
 
Abbreviations used in this paper: 
 
HA, hemagglutinin; HRP, horseradish
peroxidase; STATs, signal transducers and activators of transcription;
TcH, T cell hybridoma; Tg, transgenic. 
544
 
Th2 Differentiation by Soluble, Dimeric Peptide/MHC II/Fc Chimera
 
Among several experimental approaches aimed at modu-
lating T cell responses, such as immobilized anti-TCR
mAb (14) or altered peptide ligands (15), the peptide/
MHC molecules have been considered an attractive alter-
native. MHC class II molecules extracted from cell mem-
branes and loaded in vitro with autoreactive peptides were
able to ameliorate allergic encephalomyelitis and myasthe-
nia gravis in animal models (16, 17). Recently, several vari-
ants of peptides covalently linked to MHC class II mole-
cules have been genetically engineered (18–21). Soluble
monomers and plastic-immobilized dimers of peptide/
MHC II chimeras were shown to activate cognate T cells
(18, 20, 21). To our knowledge, no data are available rela-
tive to the immunomodulatory effects of soluble multi-
meric forms of peptide/MHC II chimeras. Herein, we pro-
vide evidence that a genetically engineered, soluble dimeric
peptide/MHC class II/Fc chimera (DEF) can polarize rest-
ing and activated CD4 T cells toward Th2 response after
interaction with TCR and CD4 molecules and subsequent
negative regulation of the STAT4 pathway of Th1 differ-
entiation.
 
Materials and Methods
 
Mice.
 
BALB/c mice were obtained from The Jackson Labo-
ratory. Transgenic (Tg) BALB/c mice express the 14.3d TCR-
 
a/b
 
specific for hemagglutinin (HA)110-120 in the context of I-E
 
d
 
class II molecules.
 
Antigens.
 
The CD4 T cell epitope HA110-120 of influenza
virus PR8/A/8/34 HA (22) and NP147-154 of influenza virus
PR8/A/8/34 (23) were prepared by solid phase Fmoc technol-
ogy and purified by reverse phase HPLC on a C2/C18 column
(Amersham-Pharmacia Biotech). Purity of the synthetic peptides
was assessed by amino acid sequencing in the Protein Core Facil-
ity at Mount Sinai School of Medicine. The DEF molecule con-
sists of the I-E
 
d
 
a
 
 and I-E
 
d
 
b
 
 extracellular domains that were
dimerized through a murine Fc
 
g
 
2a fragment at the COOH ter-
mini of I-E
 
d
 
b
 
 chain (20). The HA110-120 (SFERFEIFPKE)
CD4 T cell epitope of HA of influenza virus A/PR/8/34 was
covalently linked at the NH
 
2
 
 terminus of I-E
 
d
 
b
 
 chains as previ-
ously described and designated DEF (20). Recombinant DEF
protein was produced in the baculovirus/SF9 insect cell system
and purified by affinity chromatography on goat anti–
 
g
 
2a–
Sepharose column as described (20). MOPC 173 myeloma cells
secrete an IgG2a that was used in experiments as an isotype con-
trol for the Fc
 
g
 
2a portion of the DEF molecule. A BSA–HA110-
120 conjugate was prepared using the heterobifunctional cross-
linker 1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide (Imject
Immunogen EDC Conjugation kit; Pierce Perstorp Biotech Co.)
according to the manufacturer’s instructions. The conjugate was
purified by size exclusion chromatography on a Superose-6 col-
umn (Amersham-Pharmacia Biotech). Influenza A/PR/8/34 vi-
rus was used for immunization of BALB/c mice and for mea-
surement of the antiviral isotypes in these mice by RIA. The
virus was grown in the allantoic fluid of chicken eggs and then
purified on sucrose gradient according to standard procedures.
Chemicals were purchased from Sigma Chemical Co. unless
noted otherwise.
 
Cells.
 
TCR-HA (TCR recognizing HA110-120 peptide in
context of I-Ed class II molecules) T cells were purified from the
 
spleens of Tg mice by Ficoll-Hypaque gradient centrifugation
followed by two passages on nylon wool columns (Unisorb T&B;
Nycomed Pharmaceuticals) and incubation for 2 h at 37
 
8
 
C in
plastic dishes. The nonadherent cells were collected and mea-
sured for purity by FACS™ analysis (Becton Dickinson) using
2C11 anti-CD3
 
e
 
 mAb (American Type Culture Collection
[ATCC]) conjugated with PE and 6.5.2 clonotypic anti–TCR-
HA mAb conjugated with FITC. Such preparations contained
95% CD3
 
1
 
 cells, of which 32% expressed the TCR-HA trans-
gene. P-815 is a mouse mastocytoma cell line expressing MHC
class I H-2
 
d 
 
and lacking class II molecules (ATCC). 14-3-1 T cell
hybridoma (TcH) expresses the 14.3d TCR-
 
a/b
 
 that recognizes
HA110-120 peptide in the context of class II I-E
 
d
 
 molecules (24).
 
T Cell Proliferation Assays.
 
The proliferative response of T
cells upon incubation with various antigens was measured by a
thymidine incorporation assay. In brief, splenic cells or purified
TCR-HA T cells (5 
 
3
 
 10
 
5
 
)
 
 
 
were incubated for 72 h at 37
 
8
 
C in
the presence or absence of various antigens. Tritiated thymidine
(1 
 
m
 
Ci) was added for the last 24 h, cells were harvested on filter
papers (Skatron Inc.), and radioactivity was measured in a 
 
b
 
-scin-
tillation chamber (Amersham-Pharmacia Biotech).
 
CTL Assays.
 
Spleen cells from PR8-immunized BALB/c mice
treated or untreated with antigens on days 7, 8, and 9 after immuni-
zation were collected on day 10 after immunization and then stimu-
lated for 5 d in vitro with NP147-154 peptide (2 
 
m
 
g/2 
 
3
 
 10
 
6
 
 cells/
ml) and then incubated for 4 h at 37
 
8
 
C in 96-well V-bottomed
plates at various ratios with P-815 target cells labeled with 
 
51
 
Cr
and coated with NP147-154 peptide (20 
 
m
 
g/10
 
6
 
 cells/ml). Cell cul-
ture supernatants were measured for the amount of 
 
51
 
Cr release in
a gamma counter (Amersham-Pharmacia Biotech), and the results
were computed as percentage of cytotoxicity in triplicate samples for
each E/T ratio as follows: (experimental release 
 
2
 
 spontaneous re-
lease)/(maximum release 
 
2
 
 spontaneous release) 
 
3 
 
100. Noncoated
P-815 target cells were used to determine 
 
51
 
Cr spontaneous re-
lease. Maximum 
 
51
 
Cr release refers to the amount of 
 
51
 
Cr liber-
ated from noncoated target cells upon lysis with 5% Triton X-100.
 
FACS™ Analyses.
 
10
 
6
 
 cells in 1% PBS/BSA were singly or
doubly stained with various mAbs conjugated with fluorochrome
(1–2 
 
m
 
g/10
 
6 
 
cells/ml; PharMingen) for 30 min on ice, washed
with 3% BSA in PBS, and then fixed with 1% paraformaldehyde
in PBS. The fluorescence intensity was analyzed in an EPICS
PROFILE II Analyzer (Coulter Corp.).
 
Treatment of Mice with DEF Molecules.
 
The effects of DEF
were determined in vivo using BALB/c mice inoculated with 3.0 
 
3
 
10
 
7
 
 
 
TCR-HA Tg T cells that were injected 24 h later with 130 
 
m
 
g,
i.v. of DEF or MOPC 173 protein control (single dose injection)
or with 390 
 
m
 
g of DEF or MOPC 173 (three injections at 1-d
intervals) in 200 
 
m
 
l PBS. Spleen cells (10
 
6
 
) were isolated 1 and 6 d
after the last injection. The proliferative response to HA110-120
peptide and the amount of IL secreted in culture supernatants
were determined by [
 
3
 
H]TdR incorporation and ELISA (Cyto-
screen Immunoassay; Biosource International, Inc.), respectively.
To analyze DEF specificity in vivo, BALB/c mice were immu-
nized i.p. with 100 
 
m
 
g of OVA in PBS. 9 d later, mice were in-
jected intravenously at 24-h intervals with three 130-
 
m
 
g doses of
either DEF or MOPC 173 protein, and spleen cells were col-
lected 3 d after the last injection to measure the proliferative re-
sponse and cytokine production upon in vitro challenge with
OVA (10 
 
m
 
g/ml). The effect of DEF on Ab response was investi-
gated in BALB/c mice previously immunized with 5 
 
m
 
g, i.p. of
live influenza virus PR8/A/8/34 in PBS and then injected on
days 7, 8, and 9 after immunization with 130 
 
m
 
g, i.v. of DEF or
PBS. Blood samples were collected on days 0, 7, 8, 9, and 14 af- 
545
 
Casares et al.
 
ter immunization, and the titers of anti-PR8 isotypes were deter-
mined by RIA on individual mice sera. In brief, 96-well plates
coated with 5 
 
m
 
g/ml PR8 virus were incubated for 2 h at 37
 
8
 
C
with serum samples diluted 1:100 with 1% BSA in PBS. Plates
were washed with PBS/0.05% Tween 20 and incubated for 2 h
at 37
 
8
 
C with 50 
 
m
 
l of rabbit anti–mouse isotypes (mouse isotyp-
ing kit; Bio-Rad Labs.), washed with PBS/0.05% Tween 20, and
then incubated for 2 h at room temperature with 
 
125
 
I-goat anti–
rabbit IgG Ab (5 
 
3
 
 10
 
4
 
 cpm/well). Bound Abs were measured as
cpm in a gamma counter (Pharmacia LKB).
 
Detection of Phosphorylated Proteins.
 
Phosphorylation of p56
 
lck
 
,
ZAP-70, STAT4, and STAT6 proteins was analyzed in total cell
lysates. To detect phosphorylated p56
 
lck
 
 and ZAP-70, 2.0 
 
3
 
 10
 
7
 
TcH cells were treated for 5 min with 5 
 
m
 
g/ml soluble DEF or
medium alone. DEF was then removed by centrifugation, and
the cell pellets were lysed for 30 min on ice with 2 ml of RIPA
buffer, pH 7, containing 1% NP-40, 10 mM Tris, 150 mM
NaCl, 5 mM NaF, 2 mM Na
 
3
 
VO
 
4
 
, 5 mM Na pyrophosphate,
and a cocktail of protease inhibitors (Complete™; Boehringer
Mannheim). To detect phosphorylation of STAT4 and STAT6,
TCR-HA Tg spleen cells (6.0 
 
3
 
 10
 
7
 
) were incubated for 48 h at
37
 
8
 
C with 5 
 
m
 
g/ml of HA110-120 peptide, soluble DEF, anti-
CD3
 
e
 
 mAb 2C11, or clonotypic anti–TCR-HA 6.5.2 mAb. T
cells were purified to 
 
.
 
95% CD3
 
1
 
 T cells as described and stim-
ulated for 30 min at 37
 
8
 
C with either mouse recombinant IL-4
(40 ng/ml
 
2
 
1
 
) or IL-12 (1 ng/ml
 
2
 
1
 
) (Sigma Chemical Co.). Fur-
thermore, TcH or TCR-HA Tg cells were washed with PBS and
lysed with RIPA buffer, and 100 
 
m
 
l of total cellular lysates (0.2 mg
protein) was immunoprecipitated overnight at 4
 
8
 
C with 10 
 
m
 
g of
one of the following rabbit Abs: anti-p56
 
lck 
 
(2102-G), specific for
the COOH terminus; anti–ZAP-70 (LR), specific for an amino
acid sequence mapping within the “linker” region of ZAP-70 in
the case of TcH; anti-STAT4 (C-20), specific for a region at the
COOH terminus of mouse origin; or anti-STAT6 (M-200), spe-
cific for the amino acid region 280–480 of mouse origin (Santa
Cruz Biotechnology) in the case of purified TCR-HA T cells.
The immunoprecipitates were incubated for 2 h at room temper-
ature with 20 
 
m
 
l of 50% slurry of agarose–protein A/G (Santa
Cruz Biotechnology). The agarose–protein A/G–Ab–protein
complexes were washed twice with lysis buffer and then boiled
for 5 min in 1% SDS buffer and 5% 2-ME. Samples were electro-
phoresed in a 10–15% gradient of polyacrylamide, electrotrans-
ferred onto PVDF (polyvinylidene difluoride) membranes,
blocked with 3% BSA, and probed with RC20 antiphosphoty-
rosine mAb–horseradish peroxidase (HRP) conjugate (1:10,000;
Transduction Labs.). Bound Ab–enzyme conjugates were re-
vealed by chemiluminescence using the Supersignal
 
®
 
 substrate for
HRP (Pierce Chemical Co.) as indicated by the manufacturer.
To identify the protein of interest, PVDF membranes developed
with RC20–HRP conjugate were stripped with 0.1% SDS/1%
guanidine hydrochloride for 30 s and reprobed for 2 h at room
temperature with 10 
 
m
 
g/ml of rabbit Abs specific for p56
 
lck
 
,
ZAP-70, STAT4, or STAT6. Membranes were washed with 0.1 M
Tris/HCl/PBS/0.05% Tween 20, pH 7.5, and bound Abs were
revealed by chemiluminescence using goat anti–rabbit IgG Ab–
HRP conjugate (Santa Cruz Biotechnology).
 
Results
 
Soluble DEF Is a Potent Th2 Stimulatory Molecule.
 
We
have previously shown that a soluble, dimeric HA110-
120–I-E
 
d
 
/Fc chimera (DEF) binds stably and specifically to
HA110-120–specific 14.3d TCR-
 
a/b
 
 expressed by 14-3-1
 
TcH cells (20). Herein, we investigated the T cell response
to soluble DEF molecules. Using a protocol aimed at de-
termining the immunopotency of HA110-120 peptide ex-
pressed by various protein carriers (25), we found that solu-
ble DEF is 
 
z
 
88 times more potent in stimulating cognate
T cells than the nominal peptide. Thus, half-maximal pro-
liferation of spleen cells from naive TCR-HA Tg mice as
determined by [
 
3
 
H]thymidine incorporation assay was ob-
tained with 4.5 nM peptide carried by DEF or with 400 nM
synthetic peptide. Inhibition of antigen processing with
50 
 
m
 
M chloroquine did not significantly reduce the stimu-
latory capacity of HA110-120 synthetic peptide (12%) and
DEF (17%) (data not shown). This was expected in the case
of HA110-120 peptide, because stimulation of T cells by
synthetic peptides does not require processing.
As antigen processing did not significantly affect the
stimulatory capacity of soluble DEF, we next analyzed the
nature of DEF interaction with the cognate T cells using a
two-step in vitro culture system. In the first step, purified
resting T cells were incubated for 12 h with various doses
of soluble DEF, BSA–HA110-120 conjugate, soluble anti-
TCR clonotypic 6.5.2. mAb, or medium alone. Only T
cells treated with soluble DEF secreted IL-2 (213–510 pg/ml;
Fig. 1 A). Lack of IL-2 secretion upon incubation with
BSA–HA110-120 conjugate in the purified T cell prepara-
tion confirmed the absence of APCs, which are required
for the processing of conjugate and presentation of peptides
to T cells. It is noteworthy that the same magnitude of IL-2
secretion was observed with 0.05–5 
 
m
 
g/ml DEF but not
with 0.005 
 
m
 
g/ml DEF. Also, lack of IL-2 secretion upon
incubation with a soluble clonotypic anti-TCR mAb re-
vealed its inability to stimulate T cells (Fig. 1 A). Removal
of antigens from the cell culture and addition of irradiated
syngeneic APCs (2,200 rads) for 72 h in the second step of
the assay augmented IL-4 secretion and fostered prolifera-
tion only in 5–0.05 
 
m
 
g/ml of DEF-pretreated T cells. In
contrast, T cells pretreated with BSA–HA110-120 conju-
gate, clonotypic anti-TCR mAb, or the lowest dose of
DEF (0.005 
 
m
 
g/ml) did not secrete cytokines and did not
proliferate (Fig. 1, B and D). Addition of HA110-120–
pulsed APCs to the cultures enhanced proliferation (Fig. 1
E) and secretion of IL-4 up to two to three times only in
DEF-pretreated T cells (Fig. 1 C). Under the same culture
conditions, T cells pretreated with BSA–HA110-120 con-
jugate, clonotypic anti-TCR mAb, or 0.005 mg/ml DEF
secreted mainly IL-2 and proliferated (Fig. 1, C and E).
These results indicate that the interaction of resting T cells
with soluble DEF, but not with a soluble clonotypic anti-
TCR mAb, induced efficient IL-4–dependent prolifera-
tion. IL-4 is a potent mitogen in T cells via IL-4 nuclear
activating factor (26). As little as 0.005 mg/ml DEF was
unable to trigger a Th2 response, as no proliferative re-
sponse or cytokine production was detected at this dose.
Most likely, the Th1 response obtained in T cells treated
with 0.005 mg/ml DEF and then challenged with HA110-
120–pulsed APCs was the result of further stimulation with
HA110-120–pulsed APCs.
To determine the effect of soluble DEF on resting T546 Th2 Differentiation by Soluble, Dimeric Peptide/MHC II/Fc Chimera
cells in vivo, BALB/c mice were inoculated with TCR-
HA T cells from nonimmunized Tg mice and then injected
with 390 mg, i.v. of DEF or MOPC 173 as a control ad-
ministered at 24-h intervals as 130-mg injections. Spleen
cells from mice injected with DEF proliferated upon chal-
lenge in vitro with HA110-120 peptide (Fig. 2 A) and
showed the following kinetics of cytokine secretion: IL-2
followed an ascending pattern in control animals, while de-
scending on day 3 in all DEF-treated mice (Fig. 2 B); IL-4
was barely detected on days 2 and 3 in control animals and
significantly elevated on day 2 in all DEF-treated animals
(Fig. 2 C), and IL-10 was considerably increased in DEF-
treated mice on day 3 as compared with the control mice
(Fig. 2 D). Similar results were obtained with a single dose
of DEF (130 mg), although the magnitude of the prolifera-
tive response and cytokine production was slightly lower
(data not shown). The results clearly indicate that a quite
wide range of DEF doses (5–0.05 mg/ml) was able to in-
duce differentiation of resting, peptide-specific T cells to-
ward a Th2 phenotype.
We next analyzed the fate of activated T cells upon in-
teraction with soluble DEF. TCR-HA T cells stimulated
with HA peptide and then restimulated with DEF or HA
peptide showed a strong proliferative response, but only re-
stimulation with DEF reversed the IL-2/IL-4 ratio, with an
order of magnitude of z7 in favor of IL-4 (Table I).
When BALB/c mice were immunized intraperitoneally
with live influenza PR8 virus and then injected intrave-
Figure 1. Effects of soluble DEF on the proliferative and cytokine responses of the purified resting TCR-HA T cells. Purified TCR-HA Tg T cells
(5 3 105) were incubated for 12 h at 378C with BSA–HA110-120 (30 mg/ml) conjugate, 6.5.2 anti-TCR clonotypic mAb, and various amounts of soluble
DEF. (A) Cytokine production (pg/ml) of T cells after 12-h incubation with Ags in the absence of peptide and APCs. (B and D) cytokine production
and proliferative response, respectively, of T cells pretreated with Ags as in A and then cultured for 72 h in the presence of irradiated (2,200 rads) naive
BALB/c spleen cells as APCs (105). (C and E) Cytokine production and proliferative response, respectively, of T cells pretreated with Ags as in A and
then cultured for 72 h in the presence of irradiated (2,200 rads) naive BALB/c spleen cells as APCs (105) and HA110-120 peptide (5 mg/ml). Values rep-
resent the mean of triplicate samples 6 SD.547 Casares et al.
nously with DEF or MOPC 173 protein control, the
HA110-120–specific proliferative response in mice treated
with DEF was accompanied by a 30-fold increase in IL-4
production as compared with control mice (Table II).
These data demonstrate that DEF polarized HA110-120–
activated T cells into proficient IL-4 producers. As revealed
in BALB/c mice immunized with OVA and then treated
with DEF or MOPC 173 protein control, DEF-induced
Th2 differentiation was restricted to HA110-120–specific
T cells. The spleen cells from OVA-immunized mice that
were or were not treated with DEF mounted a vigorous
proliferative response to OVA in vitro and secreted compa-
rable amounts of IL-2 and IL-4 (data not shown).
Together, these data indicate that soluble, dimeric peptide/
MHC II/Fc molecule (DEF) can polarize resting and activated
peptide-specific T cells toward the Th2 immune response.
Figure 2. T cell proliferative
response and cytokine produc-
tion of spleen cells from mice in-
jected with DEF. BALB/c mice
adoptively transferred with
TCR-HA Tg T cells (3.0 3 107)
were injected three times at 24-h
intervals with 130 mg/ml DEF
or MOPC 173 protein control.
24 h after the last injection,
spleen cells (5 3 105) were col-
lected and challenged in vitro
with HA110-120 peptide (5 mg/
ml), and thymidine incorpora-
tion was determined in individ-
ual mice (A). Values represent
the mean of triplicate wells 6
SD (cpm). In the same culture
system, the levels of IL-2, IL-4,
and IL-10 were determined by
ELISA 2 and 3 d after challenge
with peptide (B, C, and D, re-
spectively). Values are expressed
in pg/ml for individual mice.
The percentage of TCR-HA T
cells in spleen cells was deter-
mined by FACS™ analysis using
6.5.2–FITC conjugate as previ-
ously described (20). Animals in-
jected with MOPC 173 protein
control showed 30% of TCR-
HA T cells in mouse no. 1 and
33% in mouse no. 2, and in
those injected with DEF, 44% in
mouse no. 1, 43% in mouse no.
2, 41% in mouse no. 3, and 37%
in mouse no. 4.
Table I. The Proliferative Response and Cytokine Production by Activated TCR-HA Tg T Cells Restimulated In Vitro with Soluble DEF or 
HA110-120 Peptide
Restimulation
with antigen [3H]TdR IL-2 IL-4
IL-2/IL-4
ratio
cpm pg/ml pg/ml
Nil 59,469 6 5,859 841 6 12 35 6 3 24.0
HA110-120 (5 mg/ml) 90,844 6 5,019 2,331 6 143 111 6 8 21.4
DEF (5 mg/ml) 68,627 6 4,706 774 6 9 134 6 10 5.7
TCR-HA Tg splenic cells (106/ml) were activated for 24 h in vitro with HA110-120 peptide, washed, and reincubated with HA110-120 peptide or
DEF. Values indicate the thymidine incorporation (cpm 6 SD) and the amounts of cytokines (pg/ml 6 SD) determined 3 d after restimulation in
vitro with Ags.548 Th2 Differentiation by Soluble, Dimeric Peptide/MHC II/Fc Chimera
DEF Induces Th2 Bystander Effects In Vivo. The recruit-
ment and differentiation of CD8 T cells depends greatly on
the availability of cytokines secreted by CD4 Th1 cells,
particularly IL-2. We thus investigated the extent to which
DEF-induced Th2 response in vivo may affect the cytolytic
function of CD8 T cells. BALB/c mice immunized with
live PR8 virus and then treated with DEF showed a 40%
reduction of CTL activity against target cells coated with
NP147-154 peptide (Fig. 3 A). NP147-154 is a dominant
CD8 T cell epitope of the nucleoprotein of influenza virus
A/PR/834 in H-2d mice (23). Reduced CTL activity was
correlated with a double bystander effect: IL-2 deprivation
and increase of IL-4 production. Th1-derived IL-2 is the
major growth factor required for differentiation and activa-
tion of CD8 T cells (27). Indeed, we previously found that
depletion of CD4 T cells in naive TCR-HA Tg mice re-
sulted in lack of differentiation of CTLs (28). Increase of
IL-4 after DEF treatment could also deprive CD8 T cells of
IL-2, as it is known that IL-4 and IL-10 are potent suppres-
sors of IL-2 synthesis (29).
Th1 cells mediate IgG2a, and Th2 cells mediate IgG1 Ab
response (30). We thus sought to analyze the effect of
DEF-induced Th2 polarization on the IgG1 and IgG2a Ab
responses in BALB/c mice immunized with live influenza
PR8 virus. BALB/c mice immunized with live PR8 virus
develop a mixed Th1/Th2-mediated Ab response (31).
The HA of influenza PR8 virus bears major B cell epitopes
(32) and the HA110-120 T cell immunodominant epitope
that is recognized by CD4 T cells in the context of I-Ed
class II molecules (22). Mice immunized with PR8 virus
and treated with DEF developed higher IgG1 and lower
IgG2a anti-PR8 responses than the control mice (Fig. 3 B).
This can be explained by a double bystander effect medi-
ated by elevated IL-4: enhanced transcription of g1 con-
stant region in the germline and inhibition of Th1-medi-
ated IgG2a synthesis (30). It is likely that DEF inhibited
virus-specific CTL activity in PR8-immunized BALB/c
mice by a double bystander effect (IL-2 deprivation and IL-
10–induced suppression), whereas it had no apparent by-
stander effect on the proliferative response of T cells nor on
the cytokine profile in OVA-immunized BALB/c mice.
This can be explained by a very low frequency of HA-spe-
cific T cells in OVA-immunized mice, demonstrating once
more that DEF targeting ability is specific to T cells recog-
nizing HA110-120 peptide in association with I-Edab class
II molecules.
Interaction of Soluble DEF with Cognate T Cells Depends on
both TCR and CD4 Molecules. We previously demon-
strated that DEF binds stably and specifically to 14.3d
TCR-a/b, which recognizes HA110-120 peptide in the
context of class II I-Edab molecules, and this binding was
efficiently inhibited by anti-TCR clonotypic 6.5.2 mAb
(20). We also showed that soluble DEF binds to FcgRIIb
on the surfaces of APCs (20). Herein, we investigated the
role of DEF on the HA110-120–specific response upon its
interaction with TCR, CD4, and FcgRIIb. Blocking of
TCR with clonotypic 6.5.2 mAb or CD4 with GK1.5
Table II. The Proliferative Response and Cytokine Production by 
Spleen Cells from Mice Immunized with Influenza PR8 Virus and 
Injected with DEF
Mice immunized
with PR8 virus 
and injected with
[3H]thymidine
incorporation IL-2 IL-4
IL-2/IL-4
ratio
cpm pg/ml pg/ml
MOPC 173 10,685 6 546 147 6 12 29 6 7 4.7
DEF 26,945 6 687 31 6 4 960 6 22 0.033
Spleen cells were collected from BALB/c mice immunized with live
influenza PR8 virus and treated with DEF or MOPC 173 protein con-
trol. Spleen cells (106/ml) were challenged in vitro with HA110-120
peptide, and the thymidine incorporation (cpm 6 SD) and amount of
cytokines (pg/ml 6 SD) was determined after 3 d culture. Background
of proliferation was 1,267 6 657 cpm.
Figure 3. Effect of DEF on CTL and Ab responses. (A) NP147-154–
specific CTL activity from mice immunized with live PR8 influenza virus
and treated or untreated with DEF on days 7, 8, and 9 after immuniza-
tion. Spleen cells collected on day 10 after immunization were stimulated
in vitro for 5 d with NP147-154 peptide, and CTL activity was measured
against P18 target cells coated with NP147-154 synthetic peptide. The
percentage of cytotoxicity was determined in four mice and corresponds
to the mean of triplicate samples (cpm) 6 SD. (B) IgG2a and IgG1 anti-
PR8 Ab titers in BALB/c mice previously immunized with live influenza
PR8 virus and then injected three times with 130 mg of DEF or PBS on
days 7, 8, and 9 after immunization. Values represent the mean cpm mea-
sured in triplicate blood samples 6 SD collected from individual mice on
days 0, 7, and 14 after immunization.549 Casares et al.
mAb inhibited DEF-induced proliferation of TCR-HA Tg
spleen cells. We and others have found that soluble 6.5.2
and GK1.5 mAbs have no effect on signaling T cells (20,
33). Therefore, inhibition of DEF-induced proliferation by
these Abs was the result of hindering DEF access to TCR
and CD4 molecules. In contrast, blocking of FcgRIIb on
APCs with 2.4G-2 mAb showed a weak inhibitory effect
on DEF-induced proliferation (Fig. 4). This indicated that
the stimulation of T cells by soluble DEF molecules de-
pends on its interaction with TCR and CD4 molecules and
is little influenced by the binding of DEF to FcgR on
APCs.
Interaction of Soluble DEF with TCR and CD4 Molecules
Triggers Early Biochemical Events in Cognate T Cells. To
analyze the nature of the interaction between soluble DEF
and TCR/CD4, we investigated the phosphorylation of
p56lck and ZAP-70 tyrosine kinases. p56lck associates with
the cytoplasmatic domain of CD4 molecules (34) and un-
dergoes autophosphorylation upon engagement of CD4
and CD3–TCR complex with the peptide/MHC ligands
expressed on APCs (35). Phosphorylated p56lck translocates
to the ITAM (immune receptor tyrosine-based activation
motifs) of the CD3/TCR z chain and mediates recruit-
ment and phosphorylation of ZAP-70, a tyrosine kinase
expressed exclusively in T cells (35). Phosphorylation of
p56lck and ZAP-70 is critical for triggering downstream
stimulatory events in T cells (36). We found that 5-min ex-
posure of 14-3-1 TcH to soluble DEF sufficed for phos-
phorylation of p56lck and ZAP-70, which persisted 30 min
after treatment (Fig. 5). The results demonstrated that in-
teraction of soluble DEF with the cognate TCR and CD4
molecules induced early transductional events in T cells.
Interaction of Soluble DEF with TCR and CD4 Molecules
Induces Negative Regulation of STAT4 Protein. Among the
signaling pathways mediated through the cytokine recep-
tors, activation of the cytosolic latent STATs can rapidly
modulate expression of genes responsible for Th differenti-
ation (37). We investigated the extent to which critical
STAT proteins involved in Th1 and Th2 differentiation
may be affected upon stimulation with DEF. Naive TCR-
HA Tg splenocytes were first incubated for 48 h with solu-
ble DEF, HA110-120–pulsed APCs, soluble anti-CD3
mAb, or clonotypic anti–TCR-HA mAb. The phosphory-
lation-mediated activation of STAT4 and STAT6 proteins
has been determined in the purified preparation of T cells,
shortly after stimulation with IL-12 and IL-4, respectively.
IL-12–induced phosphorylation of STAT4 was impaired in
T cells treated with DEF but not in cells treated with other
TCR ligands. Although not phosphorylated, STAT4
showed unaltered molecular size, indicating the lack of its
proteolytic degradation (Fig. 6). In contrast, IL-4–induced
phosphorylation of STAT6 was not affected in cells treated
with any of the TCR ligands, including DEF. These results
suggest that DEF-induced negative regulation of the
STAT4 pathway of Th1 differentiation may have been po-
tentiated by the STAT6 pathway of Th2 differentiation. A
predominant Th1 response in cells treated with HA110-
120–pulsed APCs may have been the result of the antago-
nist effect of STAT4 on the STAT6 pathway rather than a
Figure 4. Effects of various blocking Abs on DEF-induced prolifera-
tive response of cognate T cells. TCR-HA spleen cells (2 3 105) from
naive Tg mice were incubated with various blocking Abs (50 mg/ml),
isotype control Abs (data not shown), or medium alone. 30 min later, sol-
uble DEF or HA110-120 synthetic peptide (5 mg/ml) was added to the
cultures, and thymidine incorporation was determined after 72 h as de-
scribed in the text. Values represent the mean of cpm measured in tripli-
cate wells 6 SD.
Figure 5. Phosphorylation of p56lck and ZAP-70 tyrosine kinases in T
cells treated with DEF. TcH (2.0 3 107) were incubated for 5 min with 5
mg/ml of soluble DEF or medium alone (Nil), and total cellular lysates
were electrophoretically separated as described. (A, top) Western blot of
the immunoprecipitates developed with rabbit anti–p56lck Ab followed by
RC20 antiphosphotyrosine mAb–HRP conjugate; bottom, the same
membrane stripped and reprobed with rabbit anti–p56lck Ab followed by
goat anti–rabbit IgG–HRP conjugate. The double band indicates the
presence of both phosphorylated (upper band) and nonphosphorylated
(lower band) p56lck in the lysates of cells treated with soluble DEF but not
with medium alone. (B, top) Western blot of the immunoprecipitates ob-
tained with rabbit anti–ZAP-70 Ab and developed with RC20 antiphos-
photyrosine mAb; bottom, the same membrane stripped and reprobed
with rabbit anti–ZAP-70 Ab followed by goat anti–rabbit IgG–HRP
conjugate.550 Th2 Differentiation by Soluble, Dimeric Peptide/MHC II/Fc Chimera
negative regulation of STAT6 pathways, because both
STAT4 and STAT6 proteins were phosphorylated in these
cells. STAT4 was shown to activate a genetic program able
to antagonize the STAT6 pathway of Th2 differentiation,
whereas no antagonistic effect of STAT6 on the STAT4
pathway has yet been described (12).
Discussion
In this study, we provide evidence that a soluble dimeric
HA110-120–MHC class II molecule built on a Fcg2a scaffold
(DEF) can induce in vitro and in vivo differentiation of resting
and activated peptide-specific T cells toward the Th2 response.
Gajewsky and colleagues proposed a model of T cell dif-
ferentiation in which naive T cells secreting IL-2 upon pri-
mary stimulation in the absence of costimulation either un-
dergo Th1 development or develop into Th0 cells
secreting both IL-2 and IL-4 (33, 38). Further stimulation
of Th0 cells in the presence of costimulation induces Th1
differentiation, whereas stimulation in the absence of co-
stimulation induces a defect in IL-2 but not IL-4 produc-
tion, leading to Th2 differentiation. Similarly, stimulation
of naive HA-specific T cells with soluble DEF in the ab-
sence of APC-derived costimulatory signals induced IL-2
secretion and further differentiation toward the Th0 phe-
notype. In contrast, we found that the presence of APC-
derived costimulatory signals augmented polarization of
Th0 cells toward the Th2 rather than the Th1 phenotype.
This may be explained by different stimuli used to prime
the naive T cells, i.e., anti-CD3 mAb, which stimulates an
alternative pathway of T cell activation, versus DEF, which
stimulates the TCR pathway of T cell activation. At the
time of this writing, the extent to which costimulation may
have contributed during this stage of differentiation is un-
der investigation. We also found that the presence of HA-
pulsed APCs enhanced the IL-4 secretion of DEF-induced
Th2 cells. This is consistent with the results of McKnight et
al., demonstrating that stimulation of Th2 cells with pep-
tide/MHC class II complexes on APCs enhanced IL-4 se-
cretion (39). The authors showed that IL-4 secretion by the
Th2 cells does not require costimulation. It is thus likely
that increased IL-4 secretion detected in our system was in-
duced mainly by the interaction of APC-derived HA/
MHC complexes with HA-specific Th2 cells, rather than
APC-derived costimulatory signals.
Goldstein and colleagues showed that the requirement
for costimulation in activating naive CD8 T cells by MHC
class I/peptide ligands can be circumvented by potent sig-
naling of TCRs (40, 41). Using a costimulation-free sys-
tem, Boniface et al. demonstrated that the potency of TCR
signaling by soluble peptide/MHC class II ligands parallels
the increase in valency from two to four, whereas the
monovalent forms are inefficient in stimulating T cells (42).
The monomeric peptide/MHC class II molecules failed to
activate T cells at 20,000 times higher concentration than
the tetramers, despite the fact that TCR occupancy by the
monomeric form was significantly higher. The authors sug-
gested that multivalency-mediated TCR cross-linking,
rather than occupancy of individually engaged TCRs, may
play an essential role in triggering potent TCR signals by
peptide/MHC class II complexes. We found that indepen-
dent of antigen processing but in the presence of APC-
derived costimulation, soluble bivalent DEF was 88 times
more potent in stimulating T cells than the HA/MHC
complexes expressed on APCs.
Soluble DEF induced a potent Th2 differentiation over a
large range of doses in vitro (5–0.05 mg/ml) as well as in
vivo (130 and 390 mg). For the in vivo experiments,
MOPC 173 (g2a) was used as specificity control for DEF
bearing the exon encoding Cg2a. Although MOPC 173 is
a reasonable control, the ideal specificity control would be
a DEF-like molecule in which an irrelevant peptide such as
hen lysozyme 108–116 (43) is linked to the b1 exon. Prep-
aration of such a construct is underway in our laboratory,
to be used in future experiments aimed at evaluating the ef-
fect of DEF in autoimmune diseases.
Figure 6. Phosphorylation of STAT4
and STAT6 in T cells treated with DEF.
TCR-HA Tg splenic cells were incubated
for 48 h with HA110-120–pulsed APCs,
soluble DEF, anti-CD3 mAb, or anti–
TCR-HA clonotypic mAb. T cells were
purified and stimulated with IL-4 or IL-12,
and total cellular lysates were immunopre-
cipitated with rabbit anti–STAT4 or rabbit
anti–STAT6 Abs as described. Samples were
electrophoretically separated, electrotrans-
ferred onto PVDF membranes, and devel-
oped with RC20 antiphosphotyrosine
mAb–HRP conjugate (A and C). To con-
firm STAT4 and STAT6 identity and to en-
sure that approximately equal amounts of
proteins were present in the samples ana-
lyzed, membranes were stripped and rep-
robed with rabbit anti–STAT4 or anti–
STAT6 Abs, and bound Abs were revealed
by chemiluminescence using goat anti–rab-
bit IgG–HRP conjugate (B and D).551 Casares et al.
Hamad et al. showed that various doses of a plastic-
immobilized dimeric peptide/MHC class II chimera similar
to DEF induced a Th1-like response (21). Data suggest that
not only valency but also the physical form of a dimeric
HA/MHC ligand may dictate the outcome in Th effector
functions. This may account for a different topology of
TCR binding. Dimeric TCR ligands are able to cross-link
TCR molecules, and presumably their soluble form can
cross-link a larger number of TCRs, whereas surface im-
mobilization can limit this process. High numbers of pep-
tide/MHC TCR complexes can aggregate in large clusters
by diffusion on the cell surface. Thus, different degrees of
TCR clustering as induced by soluble versus immobilized
forms of dimeric ligands may differentially signal the devel-
opment of T cells.
The role of quantitative versus qualitative signaling of T
cells at various stages of differentiation upon interaction
with TCR ligands is controversial. It has been hypothe-
sized that the nature of TCR ligation dictates conforma-
tional changes in the cytoplasmatic domains of the CD3/
TCR complex (44), which in turn favors the engagement
of different transductional pathways able to direct the de-
velopment of T cells toward various effector functions
(45). We found that the same HA110-120 CD4 T cell
epitope of PR8 influenza virus induced different T cell re-
sponses: (a) a mixed Th1/Th2 response upon immuniza-
tion with live PR8 virus, (b) a predominant Th1 response
upon challenge with synthetic peptide in the context of I-
Edab class II molecules on APCs, and (c) a Th2 response
when the peptide was presented in the context of a soluble,
dimeric peptide/MHC class II/Fc chimeric molecule. A
soluble clonotypic anti–TCR-HA mAb was unable to
stimulate the cognate T cells, suggesting that some confor-
mational constraints cannot trigger productive signaling of
T cells.
DEF-induced Th2 differentiation depended on the in-
teraction of DEF with TCR and CD4 molecules. Viola et
al. showed that Ab-mediated blocking of CD4 molecules
precluded T cell activation (46). Consistent with this re-
port, we found that interaction of soluble DEF with CD4
and TCR molecules was significantly inhibited by Ab-
mediated blocking of CD4 and TCR molecules. Brown et
al. showed that CD4 molecules preferentially potentiate
Th2 differentiation (47). Although CD4 does not signifi-
cantly stabilize the interaction of multimeric peptides/MHC
class II chimeras with TCRs, the CD4 molecules are able
to enhance the threshold of T cell activation (21, 48). This
is because signaling of the p56lck tyrosine kinase causes
colocalization with CD4, which then rapidly undergoes
autophosphorylation and translocates to the ITAM units on
the j invariant chains of the CD3/TCR complex, where it
mediates phosphorylation of ZAP-70 tyrosine kinase (35).
We found that interaction of soluble DEF with TCR and
CD4 molecules induced early phosphorylation of both
p56lck and ZAP-70 tyrosine kinases. Both p56lck and ZAP-70
kinases are critical for triggering downstream events re-
quired for productive signaling of T cells.
Phosphorylation-mediated activation of STAT4 is a crit-
ical event for the development of Th1 cells (12), and phos-
phorylation-mediated activation of STAT6 is required for
the development of Th2 cells (13). In contrast to various
TCR ligands, such as HA110-120/MHC complexes ex-
pressed by APCs, anti-CD3 mAbs, and clonotypic anti-
TCR mAbs, soluble DEF preferentially induced Th2 dif-
ferentiation, which was correlated to negative regulation of
the STAT4 protein. STAT4 could not be phosphorylated
in T cells treated with DEF, although its structural integrity
was unaltered. Lack of STAT4 phosphorylation may ac-
count for several mechanisms, including increased activity
of protein tyrosine phosphatases, as previously demon-
strated by Haspel et al. in the case of STAT1 protein (49).
Phosphatases may rapidly dephosphorylate STAT4 or alter-
natively may dephosphorylate the docking site of STAT4
on IL-12R generated by the recruitment of JAK and Tyk
upon stimulation with IL-12. Docking of STAT4 on the
IL-12R chain is essential for its phosphorylation. Other
mechanisms that may be accounted for by lack of STAT4
phosphorylation are competition for the STAT4 docking
site by small proteins of the CIS/SOCS/JAB/SSSI family
(50), which may have been upregulated upon DEF interac-
tion with T cells, and downregulation or loss of IL-12R as
the only docking site for STAT4 protein. Disregulation
and immunodeficiency of IL-12R and/or IFN-g-Ra
chain leading to ineffective Th1 responses has been de-
scribed in individuals with severe mycotic and bacterial in-
fections (51) as well as in various types of carcinomas (52).
Whether DEF-induced negative regulation of STAT4 may
account for one of these regulatory mechanisms remains to
be investigated.
DEF polarization toward a Th2 response was also de-
tected in activated, peptide-specific T cells, in vitro as well
as in mice preimmunized with live PR8 virus. Our work-
ing hypothesis is that the peptide- or PR8 virus–induced
Th1 response was significantly diminished by negative reg-
ulation of STAT4, with compensatory augmentation of
the STAT6 pathway of Th2 differentiation. The Th2 re-
sponse induced by DEF was specific for TCR-HA T cells
in vitro as well as in vivo. DEF-like molecules may provide
a tool to dissect the intimate mechanisms of Th differentia-
tion and perhaps lead to the development of more efficient
immunotherapeutics in autoimmune diseases.
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